In this episode of FYI, Chief Futurist, Brett Winton, and Analyst Nemo Marjanovic speak with Alex Zhavoronkov, founder and CEO of Insilico Medicine. Together, they explore the promise of artificial intelligence in transforming the drug discovery process—cutting years off timelines and dramatically reducing costs. Alex shares Insilico’s journey from algorithm-first beginnings to a full-stack AI-driven biotech company, highlighting their unique “pan flute” model approach to drug development and the vision of building a “pharmaceutical superintelligence.” The discussion touches on Insilico’s clinical progress, including a molecule that recently completed a Phase 2 trial, and how its generative platforms are helping to tackle complex diseases with a focus on longevity.Key Points From This Episode:00:00:00 AI's promise in streamlining the drug discovery process00:03:06 The economics of preclinical development and AI’s role in optimization00:04:43 Potential cost and timeline reductions: $2.4B down to $600M, 13 years to 800:07:39 Comparing Insilico’s approach to peers like Recursion and AbSci00:10:35 Literature-driven vs. biology-driven models in drug discovery00:13:07 Why a dominant AI platform could reshape biotech industry consolidation00:14:57 Why biologics may be more suited to AI than small molecules00:17:35 Alex Zhavoronkov on founding Insilico and his mission in longevity science00:21:00 From algorithms to real drugs: Insilico’s transition to clinical development00:23:15 Managing the pace of AI progress vs. the slow cycle of experimental validation00:27:10 How “pharmaceutical superintelligence” enables prompt-to-drug workflows00:32:26 Validation, trust, and why Insilico runs on both old and frontier models00:39:22 The “pan flute” architecture: stacking specialized models with reinforcement learning00:42:36 Building and training a unified multimodal model for chemistry and biology00:45:32 Public data, clean pipelines, and Insilico’s automated validation lab00:50:47 The business model behind Insilico: selling candidates and licensing platforms00:55:12 Why pharma buyers care more about data room quality than pricing01:00:25 On profitability, licensing success, and the dream of a self-sustaining AI biotech01:01:38 Longevity and the search for fundamental mechanisms of aging

Ver todos los episodios